Prostate Specific Antigen ELISA Kit

Catalog No. ABIN5526768

This Colorimetric ELISA kit is designed for the quantitative measurement of Human Prostate Specific Antigen.

Quick Overview for Prostate Specific Antigen ELISA Kit (ABIN5526768)

Target: Prostate Specific Antigen (PSA)

Reactivity: Human

Detection Method: Colorimetric

Method Type: Sandwich ELISA

Detection Range: 0.04-40 ng/mL

Application: ELISA

Sample Type: Plasma, Cell Culture Supernatant, Serum

Product Details Prostate Specific Antigen ELISA Kit

Minimum Detection Limit: 0.04 ng/mL

Purpose: This assay employs the quantitative sandwich enzyme immunoassay technique for the quantitative detection of human PSA.

Analytical Method: Quantitative

Specificity: PSA

Components: plate, standard, diluent

Material not included: pipettes, tubes, reader

Application Details

Sample Volume: 100 μL

Assay Time: 3 - 4 h

Plate: Pre-coated

Restrictions: For Research Use only

Handling

Buffer: 0.02 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Target Details for Prostate Specific Antigen

Target: Prostate Specific Antigen (PSA)

Alternative Name: KLK3

Background: Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), is a glycoprotein enzyme encoded in humans by the KLK3 gene. PSA is a member of the kallikrein-related peptidase family and is secreted by the epithelial cells of the prostate gland. PSA is produced for the ejaculate, where it liquefies semen in the seminal coagulum and allows sperm to swim freely. It is also believed to be instrumental in dissolving cervical mucus, allowing the entry of sperm into the uterus. PSA is present in small quantities in the serum of men with healthy prostates, but is often elevated in the presence of prostate cancer or other prostate disorders. Obesity has been reported to reduce serum PSA levels. PSA levels can be also increased by prostatitis, irritation and benign prostatic hyperplasia producing a false positive result. PSA is not a unique indicator of prostate cancer, but may also detect prostatitis or benign prostatic hyperplasia. 30 percent of patients with high PSA have prostate cancer diagnosed after biopsy. Clinical practice guidelines for prostate cancer screening vary and are controversial due to uncertainty as to whether the benefits of screening ultimately outweigh the risks of overdiagnosis and over treatment.

NCBI Accession: NM_001030047

UniProt: P07288

Pathways: Complement System